DOCKET NO.: RTS-01

No.: EL263653905US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett and Jacqueline Wyatt

For:

Antisense Modulation of Phospholipid scramblase I Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington IC 20231



PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- The specification of the above-referenced patent application;
- An executed Leclaration or Oath and Power of Attorney;
- $\sqrt{\cdot}$ An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTC-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of ENA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- ullet Sequence listing in computer readable form in accordance with 37 C.F.R. \S 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Fate	Fee
BASE FEE				\$355.00
Total Claims	20 - 20 =	Э	X S 9=	\$0
Indep. Claims	2 - 3 =	0	x\$4()=	\$0

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500152:

- the amount of \$395.00 for the above listed fees;
- · payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR.

Triplicate copies of this transmittal are enclosed.

Date: April 5, 2001

Registration No. 37,280 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 56 East Main Street Marlton NJ 08053 (856) 810-1515

DOCKET NO.: RTS-0147

"Express Mail" Label No.: EL263653905US Date of Deposit: 450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): C. Frank Bennett and Jacqueline Wyatt

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of Phospholipid scramblase I Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: Ain G, RCI

Respectfully submitted,

Laurel Spear Bernstein Registration No. 37,280 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515